Description: Verrica is a pharmaceutical company focused on identifying, developing and commercializing innovative pharmaceutical products for the treatment of skin diseases with significant unmet needs. The company’s lead product candidate, VP-102, is currently being evaluated in two Phase 3 clinical trials for the treatment of molluscum and in a Phase 2 clinical trial for the treatment of common warts.
Home Page: www.verrica.com
VRCA Technical Analysis
44 West Gay Street
West Chester,
PA
19380
United States
Phone:
484 453 3300
Officers
| Name | Title |
|---|---|
| Mr. Ted White | Pres, CEO & Director |
| Mr. Joe Bonaccorso | Chief Commercial Officer |
| Dr. Gary Goldenberg M.D. | Chief Medical Officer |
| Mr. P. Terence Kohler | Chief Financial Officer |
| Mr. Christopher G. Hayes | Chief Legal Officer, Sec., Chief Compliance Officer & Gen. Counsel |
| Mr. Eugene Scavola | Exec. VP of Technical Operations |
| Dr. Bradley J. Catalone MBA, Ph.D. | Head of Drug Devel. |
Exchange: NASDAQ
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Pharmaceuticals |
| GIC Sub-Industry: | Pharmaceuticals |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 2.8274 |
| Price-to-Sales TTM: | 14.3949 |
| IPO Date: | 2018-06-15 |
| Fiscal Year End: | December |
| Full Time Employees: | 38 |